Ticker

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the…

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT…

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million…

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of…

Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.